Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2026)

Amneal Pharmaceuticals' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 42.89% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $19.5 million, a 32.97% decrease from a year earlier, with the FY2025 full-year figure at $22.4 million, down 22.91% from the prior year.
• Amortization of Deferred Charges grew to $3.9 million in Q1 2026 per AMRX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $8.0 million in Q3 2024 and bottomed at $2.1 million in Q1 2023.
• The 5-year median for Amortization of Deferred Charges is $3.9 million (2026), against an average of $4.4 million.
• Across the five-year window, Amortization of Deferred Charges jumped 240.03% in 2024 and sank 45.5% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $2.1 million in 2022, then jumped by 121.46% to $4.7 million in 2023, then surged by 46.16% to $6.8 million in 2024, then sank by 45.5% to $3.7 million in 2025, then grew by 4.71% to $3.9 million in 2026.
• Per Business Quant, the three latest AMRX Amortization of Deferred Charges figures stand at $3.9 million (Q1 2026), $3.7 million (Q4 2025), and $5.0 million (Q3 2025).